Michel Vounatsos, Biogen CEO (Credit: World Economic Forum/Ciaran McCrickard)

An un­ortho­dox pro­pos­al for Bio­gen's Medicare-man­dat­ed Aduhelm tri­al

Bio­gen has gone full blitz since Medicare an­nounced it would on­ly cov­er its new Alzheimer’s drug when used in clin­i­cal tri­als, ac­cus­ing the agency …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.